
The posters detail preclinical data on Protagonist drug candidates PTG-100 and PTG-200. PTG-100, a potential first-in-class oral alpha4beta7 integrin antagonist is being developed initially for moderate-to-severe active ulcerative colitis, and is currently under evaluation in a Phase 2b clinical study. PTG-200, a potential first-in-class oral Interleukin-23 receptor antagonist is being developed initially for moderate-to-severe Crohn's disease and is expected to enter the clinic this year.

**Poster Presentation Details**

**Poster Number P113:** Model-based predictions of the PTG-100 pharmacodynamic (PD) responses in Ulcerative Colitis patients.

**Date and time:** Friday February 17, 2017 -- 12:30 - 13:30 CET

**Presenting author:** Larry Mattheakis

**Poster Number P001:** The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, tracks with efficacy in a preclinical model of IBD

**Date and time:** Friday February 17, 2017 -- 12:30 - 13:30 CET

**Presenting author:** Lili Cheng

The posters will also be made available on the Investors page of Protagonist Therapeutics corporate website at [http://investors.protagonist-inc.com](http://investors.protagonist-inc.com) beginning Friday, February 17 at 6:30am ET.

**About Protagonist Therapeutics, Inc.**

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target the same biological pathways for which there are marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer preferential drug exposure in the GI tissue compartment, the potential for improved safety due to minimal exposure in the blood, improved convenience and compliance, and potentially an opportunity for the earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's oral peptide product candidates, PTG-100 and PTG-200, are based on this approach with the potential to transform the existing treatment paradigm for IBD, which includes both ulcerative colitis and Crohn's disease.

Protagonist is headquartered in Milpitas, California with its pre-clinical and clinical development staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit [http://www.protagonist-inc.com](http://www.protagonist-inc.com).
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our programs, plans, timing and the availability of results of our clinical trials and the potential for eventual regulatory approval of our product candidates. In some cases you can identify these statements by forward-looking words such as "may," "will," "continue," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our quarterly report on Form 10-Q for the quarter ended September 30, 2016 filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CONTACT: Joan Kureczka, Kureczka/Martin Associates, Tel: +1 415-821-2413, Mobile: +1 415-690-0210, email: Joan@Kureczka-martin.com; For Investors: The Trout Group, Marcy Nanus, Tel: +1 646-378-2927, Email: mnanus@troutgroup.com